New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions.
Level 5 - mechanism / opinion, no new human data
Narrative review of existing RCT and observational literature without systematic review methodology
PubMed 39815764 · doi:10.1210/clinem/dgaf026
What was done
This narrative review synthesized evidence regarding the effects of menopausal hormone therapy (MHT)—including estrogen-only therapy (ET) and estrogen-progestogen therapy (EPT)—on the risk of Alzheimer disease (AD) and all-cause dementia, focusing on the timing of initiation, age, formulation, and the utility of AD biomarkers for early outcome assessment.
What was found
Randomized clinical trials in postmenopausal women aged 65 and older showed an increased risk of dementia with MHT. Midlife randomized trials are absent, but observational studies associated midlife ET use with a reduced risk of AD and dementia, whereas EPT showed more variable outcomes. Severe MHT-related adverse risks (breast cancer, stroke, and venous thromboembolism) were reported as rare (<10 events per 10,000 women). Quantitative effect estimates for AD incidence were not provided in the abstract.
Why it matters
Because available Alzheimer's medications lack preventative efficacy, establishing whether a time-sensitive window exists for hormone therapy could inform female-specific prevention strategies and guide the design of future biomarker-driven trials.
Limits
This is a narrative review with no systematic search or meta-analytic pooling. The underlying literature lacks midlife randomized trials, exhibits high observational heterogeneity, shows inconsistent outcomes between formulations, and largely relies on conventional clinical endpoints rather than early disease biomarkers.
Cited by
- partial Starting estrogen and progesterone replacement therapy at midlife or perimenopause provides greater Alzheimer's risk reduction than initiating it postmenopausally.